JW Pharmaceutical said on the 13th that its dyslipidemia (hyperlipidemia) treatment Livalozet is also effective for patients with diabetes. It said Livalozet lowers cholesterol levels while maintaining blood sugar.
According to the company, when Livalozet was administered for 48 weeks to 408 dyslipidemia patients with diabetes, the median low-density lipoprotein cholesterol level fell from 134 mg/dL to 66 mg/dL. Low-density lipoprotein cholesterol causes arteriosclerosis and cardiovascular disease. In 416 patients without diabetes, the low-density lipoprotein cholesterol level decreased from 159 mg/dL to 76 mg/dL. Fasting blood glucose showed no notable changes during the administration period.
Patients with hyperlipidemia take statin drugs that lower blood cholesterol levels. However, statins raise blood sugar, making them difficult for patients with diabetes to take, and Livalozet addressed this issue. A JW Pharmaceutical official said, "It can reduce the treatment burden for patients with diabetes."